A universal or broadly curative therapy for most major cancer types is approved before 2035.

Question

Six frontier AI models put this at 4% by 14 Sept 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

4% — the median of 6 frontier models, resolving by 2036-09-14.

Answer

Gemini (Google): 2% — Cancer's extreme genomic heterogeneity precludes a single pan-cancer cure navigating Phase 1-3 trials by 2035. FDA trials for metastatic therapies require 7-10 years of longitudinal survival data that do not exist for any universal agent today. Even blockbuster immunotherapies like PD-1 blockers cure only minority subsets across diverse tumor microenvironments. A radical breakthrough in common neoantigen targeting entering Phase 2 by 2028 would be required to shift these odds upward.

Answer

Claude (Anthropic): 2% — Cancer biology is too heterogeneous for one therapy to cure most major metastatic cancer types by 2035. No single FDA-approved therapy today cures even one metastatic cancer type broadly, let alone most major types. Oncology drug development requires years of Phase I-III trials per cancer type, making a universal cure by 2035 implausible. mRNA and targeted therapies show promise for specific tumor antigens but face resistance, heterogeneity, and personalization barriers that block universality.

Answer

GPT (OpenAI): 12% — It turns on whether any platform can show durable cures across several metastatic solid tumors in randomized trials by 2034. FDA approvals require compelling phase III survival data, so sponsors must begin successful late-stage trials by roughly 2030-31. Across-the-board cures have no modern precedent; checkpoint and targeted drugs transformed subsets, not most common cancers. I would raise this sharply if a shared antigen or personalized mRNA regimen produced replicated long-term remissions in multiple phase II cohorts by 2029.

Answer

Grok (xAI): 8% — Turns on a pan-cancer metastatic cure finishing trials and FDA approval in under nine years. No late-stage candidate today claims broad cure of common metastatic cancers; oncology programs typically need 7–12 years from IND to approval. Checkpoint inhibitors and CAR-T set the base rate: they transformed subsets but left most solid-tumor patients uncured due to genomic heterogeneity. An off-the-shelf mRNA or allogeneic-cell platform posting multi-indication phase-3 OS wins by 2030 would shift the odds, yet none is that far along.

Answer

DeepSeek (DeepSeek): 4% — A single therapy curing most metastatic solid tumors by 2035 is a category error, not a timeline problem. Cancer is 200+ diseases; FDA approves drugs per indication, so 'most major types' would need dozens of separate trials and labels. Even the best current curative-intent drugs (checkpoint inhibitors, CAR-T) cure only subsets, often under 30% in metastatic settings. The one thing that would change this: a pan-tumor, tissue-agnostic mechanism (e.g., a universal neoantigen vaccine) showing durable cures across 10+ histologies in Phase…

Answer

Qwen (Alibaba): 3% — No single therapy has ever cured multiple metastatic cancer types simultaneously; the biological heterogeneity makes this near-impossible in 9 years. FDA approval timelines for novel oncology agents average 7-10 years from first-in-human to approval; a universal curative agent would need to clear Phase I-III across… No mechanism currently in clinical trials (mRNA vaccines, CAR-T, bispecifics) has demonstrated curative efficacy across even two distinct metastatic solid tumor types… The resolution criterion—curing multiple common metastatic cancers—has zero historical precedent; even checkpoint inhibitors, the broadest recent advance, cure only a…

A universal or broadly curative therapy for most major cancer types is approved before 2035.

AbbVie submits a regulatory filing for etentamig based on the Phase 3 CERVINO study.

The FDA withdraws marketing approval for Amgen's Tavneos.

Indonesian health ministry reports show another week-on-week increase in respiratory infections from wildfires in the next official update.